Evidence map›Paper›PMID 36040678›Full record

ArticleJournal of molecular neuroscience : MN2022

DRAXIN as a Novel Diagnostic Marker to Predict the Poor Prognosis of Glioma Patients.

Yulong Jia, Zhendong Liu, Xingbo Cheng, Runze Liu, Pengxu Li, Defu Kong, Wenjia Liang, Binfeng Liu, Hongbo Wang, Xingyao Bu and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of molecular neuroscience : MN, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Yulong Jia *Department of Neurosurgery, School of Clinical Medicine, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Henan University, Zhengzhou, China.
Zhendong Liu *Department of Orthopedics, School of Clinical Medicine, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Henan University, Zhengzhou, Henan, China.
Xingbo Cheng *Department of Microbiome Laboratory, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Runze Liu *Department of Microbiome Laboratory, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
Pengxu LiDepartment of Orthopedics, School of Clinical Medicine, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Henan University, Zhengzhou, Henan, China.
Defu KongDepartment of Orthopedics, Henan Provincial People's Hospital, Zhengzhou, Henan, China.
Wenjia LiangPeople's Hospital of Henan University, Henan Provincial People's Hospital, Henan Province, 450003, China.
Binfeng LiuPeople's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, China.
Hongbo WangPeople's Hospital of Henan University, Henan Provincial People's Hospital, Henan Province, 450003, China.
Xingyao BuDepartment of Neurosurgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, Henan, China. xingyaob@zzu.edu.cn.
Yanzheng GaoDepartment of Surgery of Spine and Spinal Cord, Henan International Joint Laboratory of Intelligentized Orthopedics Innovation and Transformation, Henan Key Laboratory for Intelligent Precision Orthopedics, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Henan, Zhengzhou, 453003, China. yanzhenggaohn@163.com.ORCID http://orcid.org/0000-0002-2937-815X
Henan University · CNZhengzhou University · CNHenan Provincial People's Hospital · CN

Funding

the thousand talents plan of central plains ZYQR20191212
6 · The paper itself

Abstract

An increasing number of evidences have shown that the carcinogenic effect of DRAXIN plays an important role in the malignant process of tumors, but the mechanism of its involvement in glioma has not yet been revealed. The main aim of this study is to explore the relationship between DRAXIN and the prognosis and pathogenesis of glioma through a large quality of data analysis. Firstly, thousands of tissue samples with clinical information were collected based on various public databases. Then, a series of bioinformatics analyses were performed to mine data from information of glioma samples extracted from several reputable databases to reveal the key role of DRAXIN in glioma development and progression, with the confirmation of basic experiments. Our results showed that high expression of the oncogene DRAXIN in tumor tissue and cells could be used as an independent risk factor for poor prognosis in glioma patients and was strongly associated with clinical risk features. The reverse transcription-quantitative PCR technique was then utilized to validate the DRAXIN expression results we obtained. In addition, co-expression analysis identified, respectively, top 10 genes that were closely associated with DRAXIN positively or negatively. Finally, in vitro experiments demonstrated that knockdown of DRAXIN significantly inhibited proliferation and invasion of glioma cell. To sum up, this is the first report of DRAXIN being highly expressed in gliomas and leading to poor prognosis of glioma patients. DRAXIN may not only benefit to explore the pathogenesis of gliomas, but also serve as a novel biological target for the treatment of glioma.

Indexed as

Brain NeoplasmsGliomaCell Line, TumorCell ProliferationHumansIntercellular Signaling Peptides and ProteinsDRAXIN protein, humanIntercellular Signaling Peptides and ProteinsBiomarkerCell cycleGliomasOncogeneProliferation

Identifiers

PMID36040678
PMCPMC9596576
OpenAlexW4293568991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.